NeoGenomics, Inc. (NEO)
| Market Cap | 5.53B |
| Revenue (ttm) | 488.70M |
| Net Income (ttm) | 71.73M |
| Shares Out | 118.29M |
| EPS (ttm) | 0.61 |
| PE Ratio | 74.87 |
| Forward PE | 222.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 376,302 |
| Open | 44.64 |
| Previous Close | 44.89 |
| Day's Range | 44.41 - 45.46 |
| 52-Week Range | 36.00 - 61.57 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 56.45 (+24.4%) |
| Est. Earnings Date | Nov 4, 2021 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or...
Financial Performance
In 2020, NeoGenomics's revenue was $444.45 million, an increase of 8.71% compared to the previous year's $408.83 million. Earnings were $4.17 million, a decrease of -47.89%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for NeoGenomics stock is "Strong Buy." The 12-month stock price forecast is 56.45, which is an increase of 24.42% from the latest price.
News
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Cente r for the us e of its Liquid Biopsy Assay s
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center f...
Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services a...
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans ...
NeoGenomics Announces Board of Directors' Transition
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT.
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people familiar with the matter. Related: Guardant Health...
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar with the matter. Related: Precision Oncology S...
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application...
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announ...
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today annou...
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 80.00% and 1.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: NeoGenomics Q2 Earnings
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.06).
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
Second-Quarter 2021 Results and Highlights: Consolidated revenue increased 40% to $122 million Clinical Services revenue increased 37% to $101 million Pharma Services revenue increased 55% to $20 millio...
Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: NeoGenomics (NEO)
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to ...
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community O...
Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading pro...
Moving Average Crossover Alert: NeoGenomics (NEO)
NeoGenomics (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced t...
Don't Let These 4 Toxic Stocks Erode Your Wealth
Spotting bloated toxic stocks on a regular basis and abandoning them at the right time is one of the secrets to a winning investment strategy.
NeoGenomics To Participate In The Bank of America 2021 Health Care Conference
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
3 Top Small-Cap Stocks to Buy Right Now
These under-the-radar names deserve investors' attention.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of -500.00% and 2.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For $390M
NeoGenomics Inc (NASDAQ: NEO) has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in England. The acquisition follows a $25 million ...
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Co...
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Pla...
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million Co...
NeoGenomics (NEO) Earnings Expected to Grow: Should You Buy?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.